Summit Therapeutics Inc. (SMMT)
| Market Cap | 13.46B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -921.62M |
| Shares Out | 744.44M |
| EPS (ttm) | -1.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,916,569 |
| Open | 17.58 |
| Previous Close | 17.49 |
| Day's Range | 17.37 - 18.17 |
| 52-Week Range | 15.55 - 36.91 |
| Beta | -1.55 |
| Analysts | Strong Buy |
| Price Target | 33.63 (+86.01%) |
| Earnings Date | Oct 20, 2025 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for SMMT stock is "Strong Buy." The 12-month stock price target is $33.63, which is an increase of 86.01% from the latest price.
News
Summit Therapeutics to Present at Upcoming Investor Conferences
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferenc...
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in China and spo...
Summit Therapeutics Raises $500 Million in Private Placement
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech institut...
Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2025 Earnings Call October 20, 2025 8:00 AM EDT Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West Mahkam Zanganeh - Co...
Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold
Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically significant overall survival data. SMMT faces heightened financing risk due to increa...
What's Going On With Summit Therapeutics Stock On Monday?
Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results.
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the ...
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsore...
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, p...
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, ...
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the grant of inducement awards of options to purchase a collective total of...
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponso...
Ten Bull Market 10-Baggers
While broad market performance has been robust, one striking aspect of this cycle has been the extraordinary gains in a handful of individual equities. Ten stocks in the large-cap Russell 1,000 have n...
Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential
Summit Therapeutics Inc. (SMMT) is a U.S.-based biopharmaceutical company. It focuses on developing innovative medicines for cancer treatment.
Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. investors ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm has initiated an inv...
CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the head...
Top 3 Health Care Stocks You'll Regret Missing In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Summit Therapeutics (SMMT) WCLC Update Call (Transcript)
Summit Therapeutics (NASDAQ:SMMT) WCLC Update Conference Call September 08, 2025 08:00 AM Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West - Vice President of ...
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Summit Therapeutics Inc. SMMT, on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer (WCLC).
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already demonstrate...
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-...
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host a call to discuss the ivonescimab data from our global Phase III clinical trial, ...
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung c...
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potential f...